Linked Life Data

20127092

Source:http://linkedlifedata.com/resource/pubmed/id/20127092

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20127092rdf:typepubmed:Citationlld:pubmed
pubmed-article:20127092lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20127092lifeskim:mentionsumls-concept:C0280100lld:lifeskim
pubmed-article:20127092lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:20127092lifeskim:mentionsumls-concept:C0123931lld:lifeskim
pubmed-article:20127092lifeskim:mentionsumls-concept:C0752079lld:lifeskim
pubmed-article:20127092lifeskim:mentionsumls-concept:C0210403lld:lifeskim
pubmed-article:20127092lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:20127092lifeskim:mentionsumls-concept:C0205269lld:lifeskim
pubmed-article:20127092lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:20127092pubmed:issue5lld:pubmed
pubmed-article:20127092pubmed:dateCreated2010-8-13lld:pubmed
pubmed-article:20127092pubmed:abstractText3-AP is a ribonucleotide reductase inhibitor and has been postulated to act synergistically with other chemotherapeutic agents. This study was conducted to determine the toxicity and antitumor activity of 3-AP with irinotecan. Correlative studies included pharmacokinetics and the effects of ABCB1 and UGT1A1 polymorphisms.lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:languageenglld:pubmed
pubmed-article:20127092pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:citationSubsetIMlld:pubmed
pubmed-article:20127092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127092pubmed:statusMEDLINElld:pubmed
pubmed-article:20127092pubmed:monthOctlld:pubmed
pubmed-article:20127092pubmed:issn1432-0843lld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:MarnochaRebec...lld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:WildingGeorge...lld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:ThomasJames...lld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:KolesarJill...lld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:HolenKyle DKDlld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:IvyS PercySPlld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:EickhoffJens...lld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:SchelmanWilli...lld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:ChoiBrian SBSlld:pubmed
pubmed-article:20127092pubmed:authorpubmed-author:AlbertiDona...lld:pubmed
pubmed-article:20127092pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20127092pubmed:volume66lld:pubmed
pubmed-article:20127092pubmed:ownerNLMlld:pubmed
pubmed-article:20127092pubmed:authorsCompleteYlld:pubmed
pubmed-article:20127092pubmed:pagination973-80lld:pubmed
pubmed-article:20127092pubmed:dateRevised2011-1-25lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:meshHeadingpubmed-meshheading:20127092...lld:pubmed
pubmed-article:20127092pubmed:year2010lld:pubmed
pubmed-article:20127092pubmed:articleTitleThe maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.lld:pubmed
pubmed-article:20127092pubmed:affiliationUniversity of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI, 53792, USA.lld:pubmed
pubmed-article:20127092pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20127092pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20127092pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
pubmed-article:20127092pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed